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Abstract Cystic echinococcosis (CE) is a widespread zoono-
sis caused by the species complex Echinococcus granulosus.
Albendazole (ABZ)—the first-line anthelminthic drug for
medical treatment of CE—is metabolized in vivo to the active
derivative ABZ-sulphoxide (ABZ-SO). Target-site ABZ-SO
concentrations in the hydatid cyst mediate the anthelminthic
effect in CE. Primary outcome of this systematic review of
individual patient data was the intra-cystic ABZ-SO concen-
tration stratified by cyst size, location, calcification status and
use of praziquantel. Studies reporting intra-cystic ABZ-SO
concentrations in humans were identified by a systematic
search. A pooled analysis of individual patient data was per-
formed to assess intra-cystic concentrations. Pharmacokinetic
data of 121 individual cysts were analysed. There was no
correlation between plasma and intra-cystic ABZ-SO concen-
trations (rho=−0.03, p=0.76). Intra-cystic drug concentra-
tions were also not associated with sex and treatment duration.
Use of praziquantel in combination with ABZ was associated
with higher plasma (median 540 vs. 240 μg/L; p=0.04) but
not intra-cystic ABZ-SO concentrations (median 220 vs.
199 μg/L; p=0.36). Relative drug concentrations in hepatic
cysts were higher than in other cysts (0.8 vs. 0.4; p=0.05).
Intra-cystic concentrations were higher in calcified than non-
calcified cysts (median 897 vs. 245 μg/L; p=0.03). There was
a trend towards higher intra-cystic concentrations in smaller
sized cysts (β = −17.2 μg/L/cm; 95th CI, −35.9 to 1.6;
p=0.07). This study demonstrates that mean intra-cystic drug
concentrations are similar to plasma concentrations on a pop-
ulation level. However, in individual patients plasma concen-
trations are not directly predictive for intra-cystic concentra-
tions. The use of booster drugs was not associated with higher
intra-cystic ABZ-SO concentrations in this analysis.
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Introduction
Cystic echinococcosis is a parasitic zoonosis caused by the
larval stage of tapeworms of the species-complex
Echinococcus granulosus. Humans serve as aberrant interme-
diate host. The disease is characterised by an almost world-
wide distribution causing significant morbidity and consider-
able socioeconomic impact in highly endemic regions (Budke
et al. 2013, 2006).
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Humans infected with E. granulosus present with
cystic lesions in virtually any organ with liver (60 %)
and lungs (20 %) being the most commonly affected.
Twenty to forty percent of individuals have multiple
cysts or multiple organs involved (McManus et al.
2003; Moro and Schantz 2009). Cysts may vary remark-
ably in size, but are usually between 1 and 15 cm
(Eckert and Deplazes 2004). Cysts may persist, grow
progressively, collapse, calcify and degrade spontane-
ously or rupture and release parasitic material. The stage
of the disease is defined by radiologic criteria issued by
WHO’s informal working group on echinococcosis
(WHO-IWGE) (Brunetti et al. 2010). In this classifica-
tion, cysts of the stages CE1 and CE2 are classified as
active, CE3a and CE3b as transitional and CE4 and
CE5 as inactive.
Anti-parasitic treatment with albendazole (ABZ) was
introduced into clinical practice almost three decades ago
(Davis et al. 1986, 1989) and is still one of the corner-
stones of management of cystic echinococcosis. It may
be used alone or in combination with surgical or inter-
ventional techniques. ABZ is a benzimidazole derivative
with poor bioavailability when administered without fatty
food. Certain drugs (e.g. praziquantel or cimetidine)—
when co-administered with ABZ—were reported to in-
crease serum- and potentially intra-cystic drug concentra-
tions (Wen et al. 1994; Cobo et al. 1998). However,
these drugs are not yet routinely recommended as it is
unknown whether the administration of a booster drug
translates into improved clinical outcome.
ABZ-SO acts mainly on the germinal layer of the cyst and
only to a lesser extent on protoscolices (Liu et al. 2015). Cure
rates of medical treatment were shown to depend on cyst
size and stage. Although it is not known whether higher
intra-cystic drug concentrations are associated with im-
proved clinical outcome, the mode of action at the target
site strongly supports this hypothesis. Similarly, monitor-
ing of ABZ-SO serum levels is recommended but data
are lacking whether serum levels are predictive for intra-
cystic drug concentrations. Measurement of intra-cystic
target site concentrations is therefore currently the best
surrogate pharmacokinetic marker for medical treatment
of human echinococcosis.
To improve our knowledge on intra-cystic drug con-
centrations of ABZ-SO in human cystic echinococcosis
and to describe its potential determinants, this systematic
review and a pooled analysis of collected data was per-
formed. Primary outcome was the intra-cystic ABZ-SO
concentration stratified by cyst size, location, calcification
status and use of booster drugs. This review provides a
systematic collation of all available evidence on intra-
cystic concentrations of ABZ-SO in the treatment of cys-
tic echinococcosis in humans and its determinants.
Material and methods
Search strategy
A systematic search strategy identifying all relevant informa-
tion on intra-cystic ABZ and ABZ-SO concentrations in echi-
nococcosis was conceived. To identify eligible publications,
BPubMed^ and BCochrane^ databases were searched with the
search terms B(albendazole*) AND (echinococc* OR
hydatid*)^ for references published until August 2014 with
all publications being considered before this date. There were
no predefined language restrictions and non-English papers
were translated for further analysis. Inclusion criteria were:
(1) human patients (i.e. no animal studies) (2) reporting of
intra-cystic drug concentrations of ABZ or ABZ-SO for indi-
vidual patients.
Study selection and data collection
Two independent researchers screened study titles for eligibil-
ity. Retrieved references were further assessed for potential
inclusion in this review. To assess methodological quality of
identified publications, a validation scale was set up and rated
by two independent researchers. Evaluation criteria are shown
in Supplementary Table 1. Risk for bias was categorized into
low, moderate and high following predefined criteria
(Supplementary Table 1 and 2). In total, nine studies contrib-
uted individual cyst data to the pooled analysis as shown in
Table 1. Data were collected and entered into a pre-built data-
base. Data were checked manually by an independent inves-
tigator. A flow chart of the study selection process is presented
in Fig. 1.
Statistical analyses
An individual patient database was constructed based on
the reported data. Each cyst was considered independent-
ly in this analysis. Standard descriptive statistics were
used to describe the study population. Absolute ABZ-
SO concentration in blood and in cyst fluid and relative
cyst concentration (blood/cyst fluid) were tested for nor-
mal distribution using d’Agostino’s test and visual in-
spection. Relative drug concentration was defined as
intra-cystic drug concentration divided by plasma con-
centration. Mann–Whitney U were used to test differ-
ences of drug concentrations for independent samples
and Wilcoxon’s rank test for dependent samples.
Logistic regression analysis was used to analyse ordinal
and metric variables and their influence on drug concen-
trations. A p value of 0.05 or less was considered as
statistically significant.
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Results
The systematic literature search identified a total of 1,307
papers, of which 1,231 were excluded by title and abstract.
A further 43 studies were excluded due to a lack of data on
intra-cystic drug concentrations. Of the remaining studies, in-
complete data (n=17), non-human research subjects (n=1)
and lack of individual patient data (n=4) led to exclusion of
respective reports. One study had to be excluded due to im-
plausibly high values (Glisović et al. 1993) and another study
presenting a single case of an intra-cerebral cyst with external
shunting (Moskopp and Lotterer 1993) because of the longi-
tudinal design. In the end, data from nine publications were
therefore included in this review (Brough et al. 1989; Capan et
al. 2009; Cobo et al. 1998; Guermouche et al. 1988; Marriner
et al. 1986; Morris et al. 1985, 1987; Saimot et al. 1983;
Skuhala et al. 2014) describing drug concentrations in indi-
vidual hydatid cysts.
Study population
Altogether, 117 patients were included with a total of 121
analysed cysts. Forty-seven patients were female, 33 were male
and in 37 patients sex was not provided. Mean age was 46 years
ranging from 6 to 77. Locations of the cystic lesions were as
following: liver (n=102), lung (n=3), abdominal wall (n=2),
pleura (n=1), spleen (n=1), kidney (n=1), stomach (n=1),
retro-peritoneum (n=1), thigh (n=1), bone (n=1) and unknown
(n=7). Cyst size was provided in a total of 22 cysts and mean
cyst size was 12.2 cmwith a range from 4.0 to 30.0 cm. Six cysts
were described as calcified, compared to 58 non-calcified cysts.
No information on calcification status was provided for 57 cysts.
Intra-cystic drug concentrations
The variables ABZ-SO serum, cyst fluid concentrations and
relative drug concentrations significantly deviate from a
Table 1 Summary of included
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location, calcification status (n = 24),




Croat Med J Sex, age, cyst location, ABZ-SO plasma
concentration, ABZ-SO intra-cystic
concentration, treatment duration, use of
praziquantel, calcification status
48
Data was available for the following variables: sex (n = 80), age (n = 68), ABZ-SO plasma concentrations
(n = 115), ABZ-SO intra-cystic concentrations (n= 121), cyst location (n = 114), calcification status (n = 64),
treatment duration (n = 118), use of praziquantel (n= 121) and cyst size (n = 22)
121 cysts in total
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normal distribution (d’Agostino test <0.001 for all variables).
Median ABZ-SO concentration in blood was 245 μg/L (25th–
75th percentile, 132–518 μg/L) compared to 200 μg/L (25th–
75th percentile, 94–434 μg/L) in cysts fluid (p = 0.05).
Median relative drug concentration was 0.7 (25th–75th per-
centile, 0.3–1.8). There was no significant correlation between
plasma and intra-cystic ABZ-SO concentrations (Spearman,
−0.029; p=0.76). A scatter plot of intra-cystic and serum con-
centrations of ABZ-SO is presented in Fig 2
Comparing blood concentrations of ABZ-SO in patients
with cysts in the liver versus other locations, no statistical
difference was observed (median 240 μg/L [25th–75th per-
centile, 132–481 μg/L] vs. 292 μg/L [25th–75th percentile,
140–640 μg/L]; Mann–Whitney U, p=0.29). There was also
no difference in intra-cystic drug concentrations between liver
and non-liver cysts (median 221 μg/L [25th–75th percentile,
111–481 μg/L] vs. 159 μg/L [25th–75th percentile, 82–
436 μg/L]; Mann–Whitney U, p=0.52). However, relative
intra-cystic ABZ-SO drug concentrations were significantly
higher in liver cysts compared to non-liver cysts (0.8 [25th–
75th percentile, 0.4–2.4] vs. 0.4 [25th–75th percentile, 0.2–
0.8]; Mann–Whitney U, p=0.05) (Table 2). Median cyst and
plasma ABZ-SO concentrations of individual studies are pre-
sented in Table 3.
Calcification status was provided for a total of 64 cysts. Six
cysts were categorized as calcified compared to 58 non-
calcified cysts. Median intra-cystic drug concentrations in cal-
cified and not calcified cysts were 897 μg/L (25th to 75th
percentile, 504–2,763 μg/L) and 245 μg/L (25th–75th
percentile, 143–499 μg/L), respectively (Mann–Whitney U
test, p= 0.03). Median relative concentrations in calcified
and non-calcified cysts were 4.1 (25th–75th percentile, 0.8–
6.4) and 1.2 (25th–75th percentile, 0.4–3.3), respectively
(p=0.57).
Information on sex of patients was provided for 80 cysts.
Forty-seven were female and 33 were male. There was no
difference between females and males in blood ABZ-SO con-
centrations (median 200 μg/L [25th to 75th percentile, 121–
526 μg/L] vs. 303 μg/L [25th–75th percentile, 128–
493 μg/L]; Mann–Whitney U test, p= 0.39), cyst fluid
concentrations (median 240 μg/L [25th to 75th percen-
tile, 111–549 μg/L] vs. 198 μg/L [25th to 75th percen-
tile, 87–425 μg/L; Mann–Whitney U test, p= 0.37) and
relative drug concentrations (median 1.2 [25th–75th per-
centile, 0.2–4.1] vs. 0.7 [25th–75th percentile, 0.2–1.6];
Mann–Whitney U test, p= 0.20) (see Table 2).
In nine cysts, praziquantel was given as a booster drug
compared to 112 cysts, in which no praziquantel was admin-
istered. The administered dose was 25 mg/kg bodyweight.
Mean concentrations of ABZ-SO in blood were 540 μg/L
(25th–75th percentile, 255–1,020 μg/L) in the praziquantel
group compared to 240 μg/L (25th–75th percentile, 132–
493 μg/L) in patients without praziquantel (Mann–Whitney
U test, p=0.04). Mean concentrations of ABZ-SO in cysts
were 220 μg/L (25th–75th percentile, 170–510 μg/L) in the
praziquantel group compared to 199 μg/L (25th–75th percen-
tile, 92–425 μg/L) in patients without (Mann–Whitney U test,
p=0.36). Mean relative cyst concentrations were 0.7 in pa-
tients with praziquantel (25th–75th percentile, 0.5–0.7) com-
pared to 0.8 (25th–75th percentile, 0.2–1.8) in patients with-
out (Mann–Whitney U test, p=0.79).
Treatment duration before measurement of cyst concentra-
tion was provided for 118 cysts. Mean duration was 25 days
with a range from 1 to 84 days. In logistic regression, there
was no statistically significant influence of treatment duration
on ABZ-SO blood concentrations (β=2.1 μg/L; 95th CI,
−3.1–7.4; p = 0.42), intra-cystic ABZ-SO concentrations
(β=−5.7 μg/L; 95th CI, −12.2–0.8; p=0.09) and relative con-
centrations (β=0.00; 95th CI, −0.05–0.04; p=0.89).
Data on cyst size was available for 22 cysts. In linear re-
gression analysis, there was an inverse correlation between
cyst size and intra-cystic ABZ-SO concentrations
(β=−17.2 μg/L; 95th CI, −35.9–1.6; p=0.07), though not
reaching statistical significance. No correlation was observed
between cyst size and relative drug concentration (β=0.00;
95th CI, −0.04–0.05; p=0.91).
Discussion
In this systematic review and pooled analysis, data on intra-
cystic ABZ-SO in human echinococcosis from all published
Fig. 1 Flow chart showing study selection process
2998 Parasitol Res (2016) 115:2995–3001
reports is provided. Intra-cystic drug concentrations were only
slightly lower than plasmatic concentrations indicating that
ABZ-SO penetrates well into the cyst. At the same time, no
intra-patient correlation between blood and intra-cystic ABZ-
SO concentrations was observed in this analysis. Individual
studies included in this review provided contradictory results.
Whereas Skuhala et al. concluded in their study that intra-
cystic ABZ-SO concentrations cannot be predicted from plas-
ma concentrations (Skuhala et al. 2014), two other studies
found evidence for a correlation between plasma and intra-
Fig. 2 Scatter plot with ABZ-SO
in venous blood (plasma) as x-
axis and intra-cystic ABZ-SO
concentration as y-axis
Table 2 Table showing plasma, intra-cystic and relative ABZ-SO concentrations in liver vs. non-liver cysts, calcified vs. not calcified cysts, female vs.
male patients and in patients with and without praziquantel as booster drug, respectively
Median (25th–75th percentile) p value
(Mann–Whitney U test)
Cyst location—liver (n= 102) vs. other (n = 12)
Plasma ABZ-SO concentration in μg/L 240 (132–481) vs. 292 (140–640) 0.29
Intra-cystic fluid ABZ-SO concentrations in μg/L 221 (111–481) vs. 159 (82–436) 0.52
Relative cyst concentration 0.8 (0.4–2.4) vs. 0.4 (0.2–0.8) 0.05
Calcification status—calcified (n= 6) vs. not calcified (n= 58)
Plasma ABZ-SO concentration in μg/L 640.0 (246–680.0) vs. 218 (114–397) 0.09
Intra-cystic ABZ-SO concentrations in μg/L 897 (504–2,763) vs. 245 (143–499) 0.03
Relative cyst concentration 4.1 (0.8–6.4) vs. 1.2 (0.4–3.3) 0.57
Sex—female (n= 47) vs. male (n= 33)
Plasma ABZ-SO concentration in μg/L 200 (121–526) vs. 303 (128–493) 0.39
Intra-cystic ABZ-SO concentrations in μg/L 240 (111–549) vs. 198 (87–425) 0.37
Relative cyst concentration 1.2 (0.2–4.1) vs. 0.7 (0.2–1.6) 0.20
Use of PZQ as booster drug—yes (n= 9) vs. no (n= 112)
Plasma ABZ-SO concentration in μg/L 540.0 (255–1,020) vs. 240.0 (132–493) 0.04
Intra-cystic ABZ-SO concentrations in μg/L 220.0 (170–510) vs. 199 (92 vs. 425) 0.36
Relative cyst concentration 0.7 (0.5–0.7) vs. 0.8 (0.2–1.8) 0.81
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cystic concentrations (Cobo et al. 1998; Saimot et al. 1983).
These findings demonstrate a high inter-personal variability of
drug distribution between blood and intra-cystic fluid.
Conclusively, ABZ-SO plasma concentrations are not reliable
surrogate markers for intra-cystic drug concentrations, which
convey the parasitocidal effects.
Intra-cystic ABZ-SO concentrations were also found to
be higher in calcified cysts compared to non-calcified le-
sions. Calcification of hydatid cysts is a sign of a transi-
tional or inactive stage and may lead to a loss of an active
barrier function by the parasite against drug penetration
and may thus explain a higher influx of the drug. An
inverse correlation between cysts size and intra-cystic
drug concentration was observed in the pooled analysis.
This finding is in line with clinical experience of medical
treatment, which is known to be less efficacious in larger
sized cysts (Stojkovic et al. 2009). Whether higher dose
regimens of ABZ may effectively circumvent this phar-
macokinetic issue will ultimately depend on the bioavail-
ability and tolerability of the drug. Further studies are
needed to address this issue and to obtain clinical data.
The effect of praziquantel (PZQ), which has been used as a
booster drug for ABZ, was evaluated in this analysis and sig-
nificantly higher blood concentrations of ABZ-SO were dem-
onstrated. However, no difference in intra-cystic and relative
concentrations was observed indicating that target site concen-
trations are not improved by the addition of PZQ. This finding
does not speak against a beneficial role of praziquantel in the
management of CE, but challenges its use as booster drug to
increase intra-cystic concentrations. However, case numbers
were limited and further trials would be helpful to further
evaluate the benefit of the drug in the setting of human cystic
echinococcosis. Further, the lack of association between treat-
ment duration and intra-cystic drug concentrations provides
evidence against significant accumulation of ABZ-SO in hu-
man hydatid cysts. This might be interpreted in a way that
better response rates in long term treatment are conveyed by
longer exposure of the parasite to ABZ-SO rather than accu-
mulation of ABZ-SO.
Interestingly, higher relative drug concentrations were
found in hepatic cysts compared to cysts of other locations
without difference in absolute intra-cystic concentrations. It
can be speculated whether the high vascularization and the
metabolisation of ABZ to ABZ-SO in the liver are responsible
for this effect. Studies of intra-cystic drug concentrations in
individual patients with cysts at multiple sites could provide
further valuable information.
This systematic review aimed to circumvent the most impor-
tant limitations in clinical research in the field of echinococcosis,
notably small sample size and lack of comparability between
sites. A total number of 121 cysts were identified for pooled
analysis providing a sufficient sample size to address the main
research questions. Based on the systematic literature search, lack
of exclusion of foreign language manuscripts, and the distribu-
tion of extracted data, we are confident for study publication bias
being low. However, due to lack of reported additional informa-
tion, sub-groups were relatively small leading to inconclusive
evidence for some secondary outcomes. These outcomes of this
systematic review should therefore be scrutinized in future clin-
ical studies or updates of published evidence. Current interna-
tional research consortia may serve as an ideal platform for these
academic undertakings. Additionally, ABZ-SO concentrations in
the intra-cystic fluid were measured although the main site of
action is the germinal layer. However, we considered intra-
cystic concentrations as the best available surrogate parameter
for target site concentrations (Liu et al. 2015).
In summary, this reviews shows that we are lacking good
pharmacokinetic data of ABZ and ABZ-SO and its interaction
with the cyst in CE. From the few available reports ABZ-SO
drug distribution into cysts seems to be satisfactory despite
considerable inter-patient variability. The usefulness of mea-
suring plasma concentrations as surrogate parameter for target
site concentrations should be tested in a formal trial. Target
site concentrations are comparatively higher in small or calci-
fied cysts. Future research should evaluate the clinical impact
of these findings and whether pharmacokinetic optimization
of therapeutic regimens may improve medical treatment of
human cystic echinococcosis.
Table 3 Median intra-cystic and
venous ABZ-SO concentrations
in microgramme per litre of
individual studies
Plasma ABZ-SO concentration
in μg/L (25th–75th percentile)
Intra-cystic ABZ-SO concentration
in μg/L (25th–75th percentile)
Brough et al. (1989) n.a. 870 (368–1,080)
Capan et al. (2009) 670 (100–1,240) 375 (160–590)
Cobo et al. (1998) 285 (175–520) 180 (100–280)
Guermouche et al. (1988) 210 (210–210) 570 (200–580)
Marriner et al. (1986) 455 (225–1,510) 90 (50–170)
Morris et al. (1985) 670 (240–2,350) 100 (80–240)
Morris et al. (1987) 304 (240–670) 81 (40–132)
Saimot et al. (1983) 280 (128–640) 504 (158–923)
Skuhala et al. (2014) 200 (104–397) 279 (166–501)
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